Results 1 to 10 of about 448,698 (356)

Cholinergic Modulation of the Immune System in Neuroinflammatory Diseases

Diseases, 2021
Frequent diseases of the CNS, such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and psychiatric disorders (e.g., schizophrenia), elicit a neuroinflammatory response that contributes to the neurodegenerative disease process itself. The
Marcella Reale, Erica Costantini
doaj   +1 more source

Autoimmune Disorders of the Nervous System: Pathophysiology, Clinical Features, and Therapy

Frontiers in Neurology, 2021
Remarkable discoveries over the last two decades have elucidated the autoimmune basis of several, previously poorly understood, neurological disorders.
Satyakam Bhagavati
doaj   +1 more source

Conduction Block in the Peripheral Nervous System in Experimental Allergic Encephalomyelitis [PDF]

, 1982
Experimental Allergic Encephalomyelitis (EAE) has been widely studied as a model of multiple sclerosis, a central nervous system (CNS) disease of unknown aetiology.
Pender, M. P., Sears, T. A.
core   +1 more source

Klotho pathways, myelination disorders, neurodegenerative diseases, and epigenetic drugs [PDF]

, 2020
In this review we outline a rationale for identifying neuroprotectants aimed at inducing endogenous Klotho activity and expression, which is epigenetic action, by definition. Such an approach should promote remyelination and/or stimulate myelin repair by
Chen, Xiaohong, Faller, Douglas V., Glavas, Ioannis P., Harpp, David N., Kanara, Iphigenia, Kodukula, Krishna, Mavrakis, Anastasios N., Moos, Walter H., Pernokas, Julie, Pernokas, Mark, Pinkert, Carl A., Powers, Whitney R., Sampani, Konstantina, Steliou, Kosta, Vavvas, Demetrios G., Zamboni, Robert J.   +15 more
core   +1 more source

Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor‐related adverse reactions in the nervous system

Thoracic Cancer, 2020
Immune checkpoint inhibitors (ICIs) can cause adverse reactions in the nervous system. The incidence rate is 0.1%–12% and 80% of nervous system adverse reactions occur within the first four months of application.
Jiayu Shi, Jingwen Niu, Dongchao Shen, Mingsheng Liu, Ying Tan, Yi Li, Yangyu huang, Liying Cui, Yuzhou Guan, Li Zhang   +9 more
doaj   +1 more source

Neurological Diseases: Cause and Effect in the Era of COVID-19

SVU - International Journal of Medical Sciences, 2021
Background: SARS-CoV-2 new infectious disease was first reported in Wuhan, China in December 2019. Thereafter, it has extensively spread causing global pandemic. It was named as corona virus disease 2019 (COVID-19) by WHO in February 2020. Other than the
Islam Elmalky *, Eptehal Dongol, Hazem Abdelkhalek   +2 more
doaj   +1 more source

Protective potential of glucagon like peptide 2 (GLP-2) against the neurodegeneration [PDF]

, 2019
Neurodegeneration consists in loss of neuron specific types, pattern and distribution, leading to progressive dysfunctions of the central nervous system.
Amato, Antonella, Mulè, Flavia
core   +1 more source

Serum amyloid A primes microglia for ATP-dependent interleukin-1\u3b2 release [PDF]

, 2018
Acute-phase response is a systemic reaction to environmental/inflammatory insults and involves production of acute-phase proteins, including serum amyloid A (SAA).
A Basu, A Franceschini, AA Culbert, AJ Sharp, AL Giuliani, AM Van Dam, B Sperlágh, C Gabay, C Marinelli, C Solà, C Volonté, CA Dinarello, CM Uhlar, D Ferrari, D Kim, DL Thiele, E Gruys, E Nishida, E Venereau, G Guillemin, G Ristori, H Yokote, I Hardardóttir, I Kushner, I Rajkovic, J Saura, JA Sloane, JS Liang, JT Guo, K Chang, K Niemi, K Selmaj, L Facci, L Facci, L Peferoen, L Probert, L Sun, L Yao, Laura Facci, LK Parvathenani, M Barbierato, M Barbierato, M Casula, M Connolly, M De Buck, M Idzko, M Li, M Sanz, Massimo Barbierato, ME Hamby, MK McCoy, Morena Zusso, MS Kindy, MT Heneka, N Chauvet, N Cheng, P Honore, Pietro Giusti, R Ebert, RA Dal Canto, RJ Rodrigues, S Kim, S Sandri, S Tanaka, SD Skaper, SD Skaper, SD Skaper, SJ Crocker, SJ Hewett, SL Passey, SM Allan, Stephen D. Skaper, SY Seong, T Kawamoto, T Miida, T Tamamoto, TF Chung, TH Holm, XQ Li, Y Kumon, Y Wang, Y Yu, YR Ji   +82 more
core   +2 more sources

Value of Neurofilament Light Chain as a Biomarker in Peripheral Neuropathy [PDF]

Zhongguo quanke yixue, 2022
Neurofilament light chain (NfL) has been identified as a biomarker of axonal injury in a variety of central nervous system diseases. The value of NfL as a biomarker in peripheral neuropathy has gained increasing attention.
SUN Xiaoling, HUANG Kaiwei, WAN Xinbei, WU Ying, LI Zhijun
doaj   +1 more source

Neuroinflammation, Mast Cells, and Glia: Dangerous Liaisons [PDF]

, 2017
The perspective of neuroinflammation as an epiphenomenon following neuron damage is being replaced by the awareness of glia and their importance in neural functions and disorders.
Alhouayek M, Amor S, Amor S, Appel SH, Bankston AN, Biber K, Biran V, Borsook D, Brenner T, Brooks TA, Buchanan MM, Bulanova E, Burnstock G, Calcia MA, Castellheim A, Chan-Ling T, Chen YJ, Choudhuri K, Christophi GP, Christy AL, Compston A, Conti P, Corrigan F, Cristino L, Cunningham C, Dirckx M, Donath MY, Done JD, D’Agostino G, Eckenhoff RG, Eggen BJ, Ellis A, Engler H, Ertürk A, Eskander MA, Esposito P, Fonken LK, Forsythe P, Freeman LC, Fullerton JN, Gao YJ, Gaudenzio N, Geppetti P, Grace PM, Grakoui A, Gregory GD, Griffin RS, Guerreiro R, Gunin AG, Hagiyama M, Hains LE, Hanisch UK, Harcha PA, Harvey GK, Hayashi R, Heneka MT, Hickman SE, Hsieh CL, Hu W, Héron A, Iadecola C, Ito A, Jay GW, Jensen TS, Ji RR, Jin Y, Jin Y, Juremalm M, Kajihara Y, Kalesnikoff J, Kalichman MW, Kamm CP, Kerstman E, Kobayashi K, Kolbinger F, Koshinaga M, Kwon C, Lange C, Lapilover EG, Laura Facci, Le Thuc O, Leon A, Levy D, Li M, Li X, Liew FY, Lozada A, Lull ME, Luongo L, Manocha GD, Marchi N, Martini R, Maslinska D, Mate I, Matsuda H, Mattila OS, McGeer PL, Medeiros R, Medic N, Medic N, Michaloudi H, Michaud M, Millan MJ, Miller G, Milligan ED, Monks CR, Morena Zusso, Myers RR, Nakae S, Nakajima A, Nathan C, Nave KA, Nelissen S, Nguyen M, Norden DM, Noriega DB, Old EA, Orr AG, Osipchuk Y, Osterberg A, Park CK, Parvathenani LK, Patti GJ, Peferoen L, Peferoen LA, Pekny M, Pelisch N, Perry VH, Perry VH, Pietro Giusti, Prinz M, Prussin C, Punzo D, Ramlackhansingh AF, Ransohoff RM, Rapp JH, Rawji KS, Riedel B, Rivat C, Rosa AC, Sakamoto A, Sastre M, Sayed BA, Silver R, Silverman AJ, Sivanandam TM, Skaper SD, Skaper SD, Skaper SD, Skaper SD, Skaper SD, Skuljec J, Smith BH, Smith JA, Sospedra M, Stephen D. Skaper, Streit WJ, Suurmond J, Terrando N, Thacker MA, Theoharides TC, Theoharides TC, Theoharides TC, Theoharides TC, Theoharides TC, Ulmann L, van Hecke O, Varma R, von Büdingen HC, Vyas H, Wang M, Wang Y, Wardlaw AJ, Watkins LR, Wohleb ES, Xie F, Young KM, Yuan H, Zarpelon AC, Zeis T, Zhang H, Zhang S, Zhang ZG, Zuo Y   +183 more
core   +1 more source